Cargando…
VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy
This investigation studies the use of volumetric‐modulated arc therapy (VMAT) to deliver the following conceptual gynecological brachytherapy (BT) dose distributions: Type 1, traditional pear‐shaped dose distribution with substantial dose gradients; Type 2, homogeneous dose distribution throughout P...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711077/ https://www.ncbi.nlm.nih.gov/pubmed/25207568 http://dx.doi.org/10.1120/jacmp.v15i5.4839 |
_version_ | 1783283002955005952 |
---|---|
author | Merrow, Caitlin deBoer, Steven Podgorsak, Matthew B. |
author_facet | Merrow, Caitlin deBoer, Steven Podgorsak, Matthew B. |
author_sort | Merrow, Caitlin |
collection | PubMed |
description | This investigation studies the use of volumetric‐modulated arc therapy (VMAT) to deliver the following conceptual gynecological brachytherapy (BT) dose distributions: Type 1, traditional pear‐shaped dose distribution with substantial dose gradients; Type 2, homogeneous dose distribution throughout PTV (BT prescription volume); and Type 3, increased dose to PTV without organ‐at‐risk (OAR) overdose. A tandem and ovoid BT treatment plan, with the prescription dose of 6 Gy to point A, was exported into the VMAT treatment planning system (TPS) and became the baseline for comparative analysis. The 200%, 150%, 130%, 100%, 75%, and 50% dose volumes were converted into structures for optimization and evaluation purposes. The 100% dose volume was chosen to be the PTV. Five VMAT plans (Type 1) were created to duplicate the Ir‐192 tandem and ovoid inhomogeneous dose distribution. Another five VMAT plans (Type 2) were generated to deliver a homogeneous dose of 6 Gy to the PTV. An additional five VMAT plans (Type 3) were created to increase the dose to the PTV with a homogeneous dose distribution. In the first set of plans, the dose given to 99% of the 200%–100% dose volumes agreed within 2% of the BT plan on average. Additionally, it was found that the 75% dose volumes agreed within 5% of the BT plan and the 50% dose volumes agreed within 6.4% of the BT plan. In the second set of comparative analyses, the 100% dose volume was found to be within 1% of the original plan. Furthermore, the maximum increase of dose to the PTV in the last set of comparative analyses was 8 Gy with similar doses to OARs as the other VMAT plans. The maximum increase of dose was 2.50 Gy to the rectum and the maximum decrease of dose was 0.70 Gy to the bladder. Henceforth, VMAT was successful at reproducing brachytherapy dose distributions demonstrating that alternative dose distributions have the potential to be used in lieu of brachytherapy. It should also be noted that differences in radiobiology need to be further investigated. PACS numbers: 87.50.‐a, 87.53.‐j, 87.55.‐x, 87.55.D‐, 87.55.dk, 87.55.de |
format | Online Article Text |
id | pubmed-5711077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57110772018-04-02 VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy Merrow, Caitlin deBoer, Steven Podgorsak, Matthew B. J Appl Clin Med Phys Radiation Oncology Physics This investigation studies the use of volumetric‐modulated arc therapy (VMAT) to deliver the following conceptual gynecological brachytherapy (BT) dose distributions: Type 1, traditional pear‐shaped dose distribution with substantial dose gradients; Type 2, homogeneous dose distribution throughout PTV (BT prescription volume); and Type 3, increased dose to PTV without organ‐at‐risk (OAR) overdose. A tandem and ovoid BT treatment plan, with the prescription dose of 6 Gy to point A, was exported into the VMAT treatment planning system (TPS) and became the baseline for comparative analysis. The 200%, 150%, 130%, 100%, 75%, and 50% dose volumes were converted into structures for optimization and evaluation purposes. The 100% dose volume was chosen to be the PTV. Five VMAT plans (Type 1) were created to duplicate the Ir‐192 tandem and ovoid inhomogeneous dose distribution. Another five VMAT plans (Type 2) were generated to deliver a homogeneous dose of 6 Gy to the PTV. An additional five VMAT plans (Type 3) were created to increase the dose to the PTV with a homogeneous dose distribution. In the first set of plans, the dose given to 99% of the 200%–100% dose volumes agreed within 2% of the BT plan on average. Additionally, it was found that the 75% dose volumes agreed within 5% of the BT plan and the 50% dose volumes agreed within 6.4% of the BT plan. In the second set of comparative analyses, the 100% dose volume was found to be within 1% of the original plan. Furthermore, the maximum increase of dose to the PTV in the last set of comparative analyses was 8 Gy with similar doses to OARs as the other VMAT plans. The maximum increase of dose was 2.50 Gy to the rectum and the maximum decrease of dose was 0.70 Gy to the bladder. Henceforth, VMAT was successful at reproducing brachytherapy dose distributions demonstrating that alternative dose distributions have the potential to be used in lieu of brachytherapy. It should also be noted that differences in radiobiology need to be further investigated. PACS numbers: 87.50.‐a, 87.53.‐j, 87.55.‐x, 87.55.D‐, 87.55.dk, 87.55.de John Wiley and Sons Inc. 2014-09-08 /pmc/articles/PMC5711077/ /pubmed/25207568 http://dx.doi.org/10.1120/jacmp.v15i5.4839 Text en © 2014 The Authors. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Merrow, Caitlin deBoer, Steven Podgorsak, Matthew B. VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy |
title | VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy |
title_full | VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy |
title_fullStr | VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy |
title_full_unstemmed | VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy |
title_short | VMAT for the treatment of gynecologic malignancies for patients unable to receive HDR brachytherapy |
title_sort | vmat for the treatment of gynecologic malignancies for patients unable to receive hdr brachytherapy |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711077/ https://www.ncbi.nlm.nih.gov/pubmed/25207568 http://dx.doi.org/10.1120/jacmp.v15i5.4839 |
work_keys_str_mv | AT merrowcaitlin vmatforthetreatmentofgynecologicmalignanciesforpatientsunabletoreceivehdrbrachytherapy AT deboersteven vmatforthetreatmentofgynecologicmalignanciesforpatientsunabletoreceivehdrbrachytherapy AT podgorsakmatthewb vmatforthetreatmentofgynecologicmalignanciesforpatientsunabletoreceivehdrbrachytherapy |